217 related articles for article (PubMed ID: 28744533)
1. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
[TBL] [Abstract][Full Text] [Related]
2. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
3. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma.
Huang X; Chen J; Wu W; Yang W; Zhong B; Qing X; Shao Z
Acta Biomater; 2020 Jun; 109():229-243. PubMed ID: 32294550
[TBL] [Abstract][Full Text] [Related]
4. MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling.
Zhan D; Zhang X; Li J; Ding X; Cui Y; Jia J
Cancer Biother Radiopharm; 2020 Apr; 35(3):223-232. PubMed ID: 32077746
[No Abstract] [Full Text] [Related]
5. Sequential release of autophagy inhibitor and chemotherapeutic drug with polymeric delivery system for oral squamous cell carcinoma therapy.
Saiyin W; Wang D; Li L; Zhu L; Liu B; Sheng L; Li Y; Zhu B; Mao L; Li G; Zhu X
Mol Pharm; 2014 May; 11(5):1662-75. PubMed ID: 24666011
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.
Chen H; Afrin S; Guo Y; Chu W; Benzinger TLS; Rogers BE; Garbow JR; Perlmutter JS; Zhou D; Xu J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238630
[TBL] [Abstract][Full Text] [Related]
7. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
[TBL] [Abstract][Full Text] [Related]
8. Augment of Oxidative Damage with Enhanced Photodynamic Process and MTH1 Inhibition for Tumor Therapy.
Hu JJ; Chen Y; Li ZH; Peng SY; Sun Y; Zhang XZ
Nano Lett; 2019 Aug; 19(8):5568-5576. PubMed ID: 31262183
[TBL] [Abstract][Full Text] [Related]
9. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of MutT homolog 1 inhibitors in human bladder cancer cells.
Lee JW; Lee S; Ho JN; Youn JI; Byun SS; Lee E
Biosci Biotechnol Biochem; 2019 Dec; 83(12):2265-2271. PubMed ID: 31362565
[TBL] [Abstract][Full Text] [Related]
11. Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents.
Miao Q; Xu D; Wang Z; Xu L; Wang T; Wu Y; Lovejoy DB; Kalinowski DS; Richardson DR; Nie G; Zhao Y
Biomaterials; 2010 Oct; 31(28):7364-75. PubMed ID: 20599267
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
[TBL] [Abstract][Full Text] [Related]
13. Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.
Kumar A; Kawamura T; Kawatani M; Osada H; Zhang KYJ
Chem Biol Drug Des; 2017 Jun; 89(6):862-869. PubMed ID: 27863017
[TBL] [Abstract][Full Text] [Related]
14. MTH1 inhibitor amplifies the lethality of reactive oxygen species to tumor in photodynamic therapy.
Zhao L; Li J; Su Y; Yang L; Chen L; Qiang L; Wang Y; Xiang H; Tham HP; Peng J; Zhao Y
Sci Adv; 2020 Mar; 6(10):eaaz0575. PubMed ID: 32181355
[TBL] [Abstract][Full Text] [Related]
15. AuNP flares-capped mesoporous silica nanoplatform for MTH1 detection and inhibition.
Gao W; Cao W; Sun Y; Wei X; Xu K; Zhang H; Tang B
Biomaterials; 2015 Nov; 69():212-21. PubMed ID: 26298289
[TBL] [Abstract][Full Text] [Related]
16. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
[TBL] [Abstract][Full Text] [Related]
17. Potent and specific MTH1 inhibitors targeting gastric cancer.
Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
[TBL] [Abstract][Full Text] [Related]
18. Development of l-Tyrosine-Based Enzyme-Responsive Amphiphilic Poly(ester-urethane) Nanocarriers for Multiple Drug Delivery to Cancer Cells.
Aluri R; Jayakannan M
Biomacromolecules; 2017 Jan; 18(1):189-200. PubMed ID: 28064504
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
20. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
